Drugs / Ascorbate-Meglumine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06433791 | Sep 2024 → May 2025 overdue | — | LadeRx LLC | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ascorbate-Meglumine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433791 ↗ |
| Modality | Diagnostic / imaging agent | “the study MRI with ascorbate-meglumine contrast agent” NCT06433791 ↗ |
| Route | Intravenous | “by intravenous administration over 1 hour” NCT06433791 ↗ |